Primary Outcomes
Measure: Maximum plasma Concentration (Cmax) of BMS-986259 in Blood serum
Time: Day 1 and Day 8
Measure: Time to reach maximum concentration in plasma (Tmax) of BMS-986259 in blood serum
Time: Day 1 and Day 8
Measure: Area under the concentration- time curve over the dosing interval of BMS-986259 in blood serum - AUC(TAU)
Time: Day 1 and Day 8
Measure: Concentration of BMS-986259 in blood serum at 24 hours (C24)
Time: Day 1 and Day 8
Measure: Area under the concentration-time curve of BMS-986259 from time 0 (dosing) to the time of the last quantifiable - AUC(0-T)
Time: Day 8
Measure: Accumulation ratio in the maximum plasma concentration of BMS-986259 in blood serum -AR(Cmax)
Time: Day 8
Measure: Accumulation ratio of Area under the concentration-time curve in BMS-986259 over the dosing interval -AR (AUC [TAU])
Time: Day 8
Measure: Accumulation ratio concentration of BMS-986259 at 24 hours- AR(C24)
Time: Day 8
Measure: Terminal elimination half-life of BMS-986259 (T-HALF)
Time: Day 8
Measure: Apparent total clearance of BMS-986259 at steady-state (CLss/F)
Time: Day 8
Measure: Apparent volume of distribution of BMS-986259 at terminal phase at steady-state (Vss/F)
Time: Day 8
Secondary Outcomes
Measure: Incidence of Non serious Adverse Events (AEs)
Time: Up to 4 months
Measure: Incidence of Serious Adverse Events (SAEs)
Time: Up to 4 months
Measure: Incidence of AEs leading to discontinuation
Time: Up to 4 months
Measure: Number of clinically significant changes in vital signs
Time: Up to 4 months
Measure: Number in clinically significant changes in Electrocardiogram (ECG)
Time: Up to 4 months
Measure: Number of clinically significant changes in physical examinations
Time: Up to 4 months
Measure: Number of clinically significant changes in clinical laboratory tests
Time: Up to 4 months